AA
ESPR

ALPS Advisors’s Esperion Therapeutics ESPR Stock Holding History

ALPS Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-34,653
Closed -$418K – 921
2021
Q3 		$418K Sell
34,653
-2,480
-7% -$36.1K ﹤0.01% 526
2021
Q2 		$785K Sell
37,133
-13,296
-26% -$320K 0.01% 438
2021
Q1 		$1.42M Buy
50,429
+135
+0.3% +$3.98K 0.01% 357
2020
Q4 		$1.31M Buy
+50,294
New +$1.51M 0.01% 361

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

ALPS Advisors's ESPR Position: Q4 2021 in Review

ALPS Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 34,653 shares — an estimated $418K sold.

ALPS Advisors first reported a position in ESPR in Q4 2020 and held it in 4 quarters. The position peaked at $1.42M in Q1 2021. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

  • ALPS Advisors reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • ALPS Advisors sold 34,653 Esperion Therapeutics shares in Q4 2021, an estimated $418K.
  • ALPS Advisors first reported a position in Esperion Therapeutics in Q4 2020 and held it in 4 quarters.
  • ALPS Advisors's Esperion Therapeutics position peaked at $1.42M in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.